Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Chaumont-Gistoux – page 148

1 874 clinical trials in Chaumont-Gistoux, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Chaumont-Gistoux at a glance
1 874
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 874 trials in Chaumont-Gistoux

Open in trial search

Dyspepsia

Not recruiting

Study on Reducing Proton Pump Inhibitor Use in Patients with Heartburn, Reflux, or Dyspepsia: Comparing On-Demand Use, Alginate Therapy, and Gradual Dose Reduction

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aluminium Oxide
  • Sponsor:UZ Leuven

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Multiple sclerosis+4

Not recruiting

Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Antwerp University Hospital

Study on the Safety and Effectiveness of Guanfacine Hydrochloride and Atomoxetine Hydrochloride for Children and Adolescents with ADHD Aged 6 to 17 Years

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Guanfacine
  • Sponsor:Takeda Development Center Americas Inc.

Netherton's syndrome

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effect of DA-EPOCH-R and Nivolumab in Patients with Newly Diagnosed High-Grade B-Cell Lymphoma with MYC and BCL2/BCL6 Rearrangements

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Fallopian tube cancer+1

Not recruiting

Study on Treatment for Recurrent Platinum-Sensitive Ovarian, Peritoneal, or Fallopian Tube Cancer Using Carboplatin and Mirvetuximab Soravtansine in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Study on Metreleptin for Children Under 6 with Generalized Lipodystrophy and Related Diabetes or High Triglycerides

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Metreleptin
  • Sponsor:Amryt Pharmaceuticals Designated Activity Company

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Myelofibrosis+2

Not recruiting

Continued Treatment Study for Patients with Myelofibrosis, Post-Lung Transplant BOS, or Chronic Graft-Versus-Host Disease Using Itacitinib

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Incyte Corp.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Chaumont-Gistoux

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This research evaluates different approaches to medication management for individuals with functional dyspepsia and reflux conditions.

  • PPI De-prescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Approaches

The study explores on-demand medication use and alternative therapeutic options, aiming to establish optimal treatment protocols for long-term digestive health management.

02 Digestive Health Studies

Research examining the effectiveness of different management strategies for heartburn and reflux symptoms. The trials evaluate various therapeutic approaches, including alginate formulations as alternative treatments.

  • Symptom Management
  • Treatment Optimization
  • Patient-Centered Care

These investigations aim to improve quality of life for patients while identifying more targeted and efficient treatment strategies.

03 Primary Care Innovation

Forward-thinking research in primary care settings focusing on medication optimization and patient-centered approaches to chronic condition management.

  • Medication Management
  • Evidence-Based Protocols
  • Clinical Practice Enhancement

This research aims to establish better guidelines for long-term medication management in primary care practices.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.